Helena Carreira on fracture risk in cancer su...

The burden of musculoskeletal diseases is increasing. Dr Ara Nazarian tells us more about the issues surrounding this and how care can be improved in the USA.Read the full paper: https://www.thelancet.com/journals/lanhl/article/PIIS2666-7568(25)00026-1/fulltext?dgcid=buzzsprout_ic ...  Show more

Socioeconomic status impacts the onset and duration of severe disabilities, but what does this means for public health policy? Andrew Kingston (Newcastle University, UK) talks to Editor-in-Chief of The Lancet Healthy Longevity Philippa Harris about his study on socioeconomic ineq ...  Show more

In this episode, we review the high-yield topic of⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ...  Show more

Dr. Wanda Cui (Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Australia) discusses her Review on measuring ovarian toxicity in clinical trials.

Read the full article:
<a href='https://www.thelancet.com/journals/lanonc/article/PIIS1470-20 ...

Who’s really at risk for fractures, and how should we be treating them? Most fragility fractures occur in patients without osteoporosis. Should we rethink who gets treated? And could just one or two IV infusions (spread years apart) of zoledronate prevent fractures for years? Hav ...  Show more

"Cancer doesn't have to be a death sentence. It can be an awakening to a whole new way of living." - Dr. Nasha Winters Today, I sit down with Dr. Nasha Winters for an eye-opening conversation about revolutionizing cancer care. From her own journey surviving stage 4 ovarian cance ...  Show more